FeesSafety
Pluang+

Aura Biosciences advances with strong cash and Phase 3 trial for eye cancer expected in 2027

Market News
31 Oct 2026, 14:33 WIB
Seeking Alpha
View Source
Bullish
Aura Biosciences advances with strong cash and Phase 3 trial for eye cancer expected in 2027

Aura Biosciences is positioned as a low-risk, fully funded company focusing on bel-sar treatment for early choroidal melanoma, with pivotal Phase 3 trial data expected in 2027. The company holds $323.8 million in cash as of June 2026, supporting operations through the first half of 2029 and removing near-term financing concerns. Aura's strategic shift to ocular oncology, leadership changes, and workforce cuts aim to streamline efforts and focus on a niche market with little competition. Despite trading near its cash value, Aura's late-stage asset and strong trial design suggest undervaluation in the market.

Aura Biosciences is the focus of this update, with Pluang providing a snapshot of the health sector market as of Oct 31, 2026, 15:21 WIB. Among 150 health-sector US stocks priced on Pluang, 40 advanced while 108 declined today. Notable movers include ResMed Inc. (RMD) at USD 229.94, down 9.05% with a typical hold time of 52 days, Bruker Corporation (BRKR) at USD 57.07, down 7.95% with a 22-day hold, and Maravai LifeSciences (MRVI) at USD 7.81, down 7.68% with a 12-day hold.

More News

ArcaTrader launches 24/7 perpetuals trading for brokers and prop firms via Hyperliquid.

ArcaTrader launches 24/7 perpetuals trading for brokers and prop firms via Hyperliquid.

ArcaTrader has introduced 24/7 perpetuals trading powered by Hyperliquid on its multi-asset platform, allowing brokers and prop firms to offer continuous perpetuals alongside CFDs through one integrated system. This expansion enhances ArcaTrader's ex...

Others
Bullish
1 hour ago
Tempus AI reports 23% revenue growth and $193M from new data deals over 5 years

Tempus AI reports 23% revenue growth and $193M from new data deals over 5 years

Tempus AI reported a 23% year-over-year revenue increase to $411.5 million in Q3 2026, driven by rising test prices and multiyear biopharma licensing agreements expected to generate $193 million over five years. The company also anticipates an $80 mi...

Company Fundamentals
Bullish
1 hour ago
Planet Labs secures new rocket launches from Stoke Space as SpaceX plans to retire Falcon 9 by 2028

Planet Labs secures new rocket launches from Stoke Space as SpaceX plans to retire Falcon 9 by 2028

Planet Labs, which operates the largest Earth observation satellite fleet, faces a challenge as SpaceX plans to retire its Falcon 9 rockets by 2028. To maintain its satellite launches, Planet Labs has signed a multi-launch agreement with Stoke Space ...

Market News
Bullish
1 hour ago
Sigma Lithium cuts short-term debt 85%, targets 330,000 tons lithium production in 2027 with low costs.

Sigma Lithium cuts short-term debt 85%, targets 330,000 tons lithium production in 2027 with low costs.

Sigma Lithium reduced its short-term debt by 85% through a $125 million convertible note refinancing, easing financial pressure for expansion. The company reported low all-in sustaining costs of $642 per ton, well below the average lithium price of $...

Company Fundamentals
Bullish
1 hour ago
Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.

Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.

Novartis projects a 5% compound annual growth rate (CAGR) in net sales from 2026 to 2031 and aims to restore its core operating income margin to over 40% by 2029. The company raised peak sales forecasts for key drugs Kesimpta, Scemblix, and Leqvio, r...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App